TRIPLE NEGATIVE BREAST NEOPLASMS

This study tests whether adding the immunotherapy drug pembrolizumab to the chemotherapy drug capecitabine after surgery can help prevent triple-negative breast cancer from coming back. It is for people whose cancer still had some tumor left after initial chemo and immunotherapy.…

This early-phase study tests a new daily pill, NKT3964, that breaks down a protein called CDK2 to slow cancer growth. It is for adults with advanced solid tumors (like ovarian, endometrial, breast, gastric, or lung cancer) that have not responded to standard treatments. The study…

This early-phase trial tests whether freezing a tumor (cryoablation) can boost the immune system's response to the drug pembrolizumab in people with advanced triple-negative breast cancer. About 30 participants will either receive the combination or pembrolizumab alone. The goal …

This study tests a new drug, BMS-986340, alone or with other cancer treatments (nivolumab or docetaxel) in people with advanced solid tumors that have worsened after standard therapy. The goal is to find safe doses and understand side effects. About 949 adults with various cancer…

This trial tests a new drug called UCB4594, an antibody that targets a protein (HLA-G) found on many cancer cells. The goal is to see if it helps the immune system attack tumors. It is for people with advanced solid tumors (like lung, breast, or colon cancer) that have not respon…

This study tests whether combining two drugs, bicalutamide and abemaciclib, can control a rare form of advanced breast cancer called androgen receptor-positive triple-negative breast cancer. About 53 women with inoperable or metastatic disease will receive the treatment. The main…

This study tests whether adding a targeted therapy called Sac-TMT to standard chemotherapy and immunotherapy (pembrolizumab) can eliminate more cancer before surgery in people with high-risk, early-stage triple-negative or hormone-receptor-low/HER2-negative breast cancer. About 2…

This study tests whether a new drug, sacituzumab tirumotecan, given alone or with pembrolizumab, helps people with advanced triple-negative breast cancer live longer or keep the cancer from growing compared to standard chemotherapy. About 1,000 adults whose cancer has spread and …

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…

This study tests a new drug called LY4170156 in people with advanced solid tumors, such as ovarian, lung, and breast cancers. The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has two parts: first to find the safest dose, then to see how w…